Anti-Infectives · LP-029
Cefixime Tablets
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-029Anti-Infectives
- Generic identity
- CefiximeTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-029
- Generic identity
- Cefixime
- Presentation
- Tablet
- Catalogue strength
- 200 mg; 400 mg
- Catalogue pack
- Blister 1 x 10 tablets
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: cefixime.
- Dosage form: tablet.
- Proposed strengths: 200 mg and 400 mg.
- General catalogue pack: blister 1 × 10 tablets.
Layer 02 · Unresolved product-specific fields
- Exact cefixime chemical form/basis, coating, score and release characteristics for each strength.
- Whether the same 1 × 10 pack applies to both strengths as controlled SKUs.
- Approved indication/age eligibility and whether any formulation-specific substitution restrictions apply.
- Storage, shelf life, registration, manufacturing route and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 200 mg | Tablet | — | Catalogue lists blister 1 × 10 tablets; strength-specific SKU evidence not supplied | Do not infer score, coating, divisibility or equivalence from the strength alone. |
| B | 400 mg | Tablet | — | Catalogue lists blister 1 × 10 tablets; strength-specific SKU evidence not supplied | Do not infer score, coating, divisibility or equivalence from the strength alone. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Cefixime is an oral cephalosporin antibiotic for selected infections caused by susceptible bacteria. Its oral forms include tablets and suspension presentations, but pharmaceutical equivalence should not be inferred from the ingredient name alone. The infection, local resistance situation and authorized product information determine appropriate use. This educational profile describes cefixime generally and does not constitute a Luang Pharma indication, registration claim or statement of therapeutic equivalence.
Clinical context and therapeutic role
Professional selection requires attention to the suspected pathogen, microbiological evidence when available, and the most appropriate antibiotic for the diagnosis. A broad-spectrum classification is not a reason to use it for uncomplicated viral symptoms. Tablet and suspension presentations may have different product-specific recommendations, so any switch needs confirmation. A clinical review should address beta-lactam allergy, kidney function, concomitant medicines and the plan for assessing treatment response.
Selected safety context
Diarrhoea, nausea and abdominal discomfort may occur. Severe allergic reactions, serious skin reactions and antibiotic-associated colitis are important risks. A history of cephalosporin or penicillin reactions requires careful evaluation rather than an assumption that another beta-lactam is safe. Kidney disease can affect treatment decisions. New bleeding, severe persistent diarrhoea, jaundice, breathing difficulty or facial swelling needs medical assessment. Do not change between formulations solely by comparing the number of milligrams.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue describes a tablet presentation. The exact salt, coating, score line and release characteristics need confirmation from the authorized product information. A milligram strength identifies ingredient quantity; it does not establish whether a tablet may be split, crushed or exchanged for another formulation.
Keep the product in its labeled packaging so the batch, expiry and instructions remain identifiable. Follow the actual label for storage conditions and disposal. Do not use a damaged or unidentified tablet, and keep all medicines securely out of children’s reach.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A qualified prescriber should establish the infection and need for treatment, consult current local guidance and resistance information where relevant, and select a suitable route. Generic reference literature is not a substitute for the authorized local product information.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification and quantitative composition for each exact presentation.
Approved/controlled label or leaflet for the intended jurisdiction.
Strength/form-to-pack SKU matrix and controlled packaging artwork where more than one variant is listed.
Registration/market-status and manufacturing-site evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07b checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| DailyMed: Cefixime tablet — official US label exampleArchived source classification: US official drug label example | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
| DailyMed: Cefixime powder for suspension — official US label exampleArchived source classification: US official drug label example | Source revision recorded: Label updated 14 February 2024; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-029.
Professional enquiries
Request product-specific evidence for LP-029.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.